Theraclone Sciences, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2004-01-01
- Employees
- 11
- Market Cap
- -
Influenza Virus Challenge Study to Test Monoclonal Antibody TCN-032 as a Treatment for Influenza
Phase 2
- Conditions
- Influenza
- Interventions
- Biological: Placebo (saline)Biological: TCN-032
- First Posted Date
- 2012-11-01
- Last Posted Date
- 2012-11-01
- Lead Sponsor
- Theraclone Sciences, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT01719874
Safety Study of Human Anti-Cytomegalovirus Monoclonal Antibody
Phase 1
Completed
- Conditions
- Cytomegalovirus Infections
- Interventions
- Biological: TCN-202Biological: Placebo
- First Posted Date
- 2012-05-09
- Last Posted Date
- 2014-03-21
- Lead Sponsor
- Theraclone Sciences, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT01594437
- Locations
- 🇺🇸
SNBL Clinical Pharmacology Center, Baltimore, Maryland, United States
Safety Study of Anti-Influenza Virus Monoclonal Antibody to Treat Influenza
Phase 1
Completed
- Conditions
- Influenza, Human
- Interventions
- Biological: TCN-032Biological: Placebo
- First Posted Date
- 2011-07-08
- Last Posted Date
- 2012-04-02
- Lead Sponsor
- Theraclone Sciences, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT01390025
- Locations
- 🇺🇸
SNBL Clinical Pharmacology Center, Baltimore, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath